Categories: News

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

Recent Posts

Genflow Completes Dosing Phase of Canine Gene Therapy Trial

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION…

2 hours ago

President Trump Cleaning Up Biden’s Marijuana Mess – MMJ Preparing to Move FDA Huntington’s Cannabis Trials Forward

Trump Prepares to Clean Up Biden's "Do-Nothing" Marijuana Mess: Why MMJ International Holdings Takes the…

2 hours ago

Meridian Innovation Redefining Low-Cost Thermal Imaging for the AI Era

TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Meridian Innovation's Cheetah thermal imaging sensor claimed this year's Best…

5 hours ago

Atomathic Launches AISIR For Radar — Physical AI Reasoning Technology for Safety-Critical Perception

New White Paper Details the Dual-System Architecture Behind AISIR for Radar™ and How Atomathic Closes…

5 hours ago

Healthcare Payer IT in 2026: Digital Prior Authorization, Enforceable Transparency, and Outcomes-Driven Platforms Spark a New Acquisition Race

CMS compliance deadlines and heightened cybersecurity expectations are accelerating payer interoperability and utilization management modernization…

8 hours ago